The ABCDE approach in critically ill patients: A scoping review of assessment tools, adherence and reported outcomes

Autor: Laura J. Bruinink, Marjolein Linders, Willem P. de Boode, Cornelia R.M.G. Fluit, Marije Hogeveen

Publikováno v: Resuscitation Plus, Vol 20, Iss , Pp 100763- (2024)

Aim: The systematic Airway, Breathing, Circulation, Disability, and Exposure (ABCDE) approach is a priority-based consensus approach for the primary assessment of all categories of critically ill or injured patients. The aims of this review are to pr

Externí odkaz: https://doaj.org/article/ec9ea0e05144450ebb87252ba8575f0f

P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA

Autor: Mattia D’agostino, Davine Hofste Op Bruinink, Mark van Duin, Delia Rota-Scalabrini, Luca Bertamini, Rowan Kuiper, Angelo Belotti, Vincenzo Marasco, Stefania Oliva, Elena Rivolti, Jennifer Rogers, Roberto Mina, Mariella Grasso, Antonio Ledda, Massimo Offidani, Monica Galli, Michele Cavo, Annemiek Broijl, Pellegrino Musto, Benedetto Bruno, Mario Boccadoro, Pieter Sonneveld, Francesca Gay

Publikováno v: HemaSphere, Vol 7, p e36094ab (2023)

Externí odkaz: https://doaj.org/article/3b796f80d4e14f24afec4a2aa1b32606

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Autor: Stefania Oliva, Davine Hofste op Bruinink, Lucie Rihova, Mattia D’Agostino, Lucia Pantani, Andrea Capra, Bronno van der Holt, Rossella Troia, Maria Teresa Petrucci, Tania Villanova, Pavla Vsianska, Romana Jugooa, Claudia Brandt-Hagens, Milena Gilestro, Massimo Offidani, Rossella Ribolla, Monica Galli, Roman Hajek, Francesca Gay, Michele Cavo, Paola Omedé, Vincent H. J. van der Velden, Mario Boccadoro, Pieter Sonneveld

Publikováno v: Blood Cancer Journal, Vol 11, Iss 6, Pp 1-9 (2021)

Abstract Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnose

Externí odkaz: https://doaj.org/article/fff4989bfcb448fa8d1e3442a6743211

Analytical performance of a single epitope B-type natriuretic peptide sandwich immunoassay on the Minicare platform for point-of-care diagnostics

Autor: Reenen, Alexander van, Berger, Mario, Moreau, Emmanuel, Bekx, Edwin, Bruinink, Tom, Kemper, Danielle, Lippen, Lian van, Weusten, Jos, Mrakovic, Anita, Michielsen, Etienne, Vissers, Joost, Theije, Femke de, Nieuwenhuis, Jeroen, Semjonow, Veronique, Mair, Johannes

Publikováno v: In Practical Laboratory Medicine May 2019 15

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile

Autor: Davine Hofste op Bruinink, Rowan Kuiper, Mark van Duin, Tom Cupedo, Vincent H.J. van der Velden, Remco Hoogenboezem, Bronno van der Holt, H. Berna Beverloo, Erik T. Valent, Michael Vermeulen, Francesca Gay, Annemiek Broijl, Hervé Avet-Loiseau, Nikhil C. Munshi, Pellegrino Musto, Philippe Moreau, Sonja Zweegman, Niels W.C.J. van de Donk, Pieter Sonneveld

Publikováno v: Hofste op Bruinink, D, Kuiper, R, van Duin, M, Cupedo, T, van der Velden, V H J, Hoogenboezem, R, van der Holt, B, Beverloo, H B, Valent, E T, Vermeulen, M, Gay, F, Broijl, A, Avet-Loiseau, H, Munshi, N C, Musto, P, Moreau, P, Zweegman, S, van de Donk, N W C J & Sonneveld, P 2022, ' Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 27, pp. 3132-3150 . https://doi.org/10.1200/JCO.21.01217
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(27), 3132-3150. American Society of Clinical Oncology

PURPOSE Primary plasma cell leukemia (pPCL) is an aggressive subtype of multiple myeloma, which is distinguished from newly diagnosed multiple myeloma (NDMM) on the basis of the presence of ≥ 20% circulating tumor cells (CTCs). A molecular marker f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55ad5570202b354aad1d11a244b64a10
https://doi.org/10.1200/jco.21.01217